174 related articles for article (PubMed ID: 34953915)
1. MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages.
Kato H; Tateishi K; Fujiwara H; Nakatsuka T; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Otsuka M; Iwadate D; Oyama H; Kanai S; Noguchi K; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito K; Saito T; Takahara N; Kishikawa T; Hamada T; Takahashi R; Miyabayashi K; Mizuno S; Kogure H; Nakai Y; Hirata Y; Toyoda A; Ichikawa K; Qu W; Morishita S; Arita J; Tanaka M; Ushiku T; Hasegawa K; Fujishiro M; Koike K
Gastroenterology; 2022 Apr; 162(4):1272-1287.e16. PubMed ID: 34953915
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms.
Huang B; Trujillo MA; Fujikura K; Qiu M; Chen F; Felsenstein M; Zhou C; Skaro M; Gauthier C; Macgregor-Das A; Hutchings D; Hong SM; Hruban RH; Eshleman JR; Thompson ED; Klein AP; Goggins M; Wood LD; Roberts NJ
J Pathol; 2020 Nov; 252(3):252-262. PubMed ID: 32696980
[TBL] [Abstract][Full Text] [Related]
3. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.
Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S
Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920
[TBL] [Abstract][Full Text] [Related]
5. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
6.
Collet L; Ghurburrun E; Meyers N; Assi M; Pirlot B; Leclercq IA; Couvelard A; Komuta M; Cros J; Demetter P; Lemaigre FP; Borbath I; Jacquemin P
Gut; 2020 Apr; 69(4):704-714. PubMed ID: 31154393
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
Fukuda A
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
[TBL] [Abstract][Full Text] [Related]
8. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic
Fujikura K; Hosoda W; Felsenstein M; Song Q; Reiter JG; Zheng L; Beleva Guthrie V; Rincon N; Dal Molin M; Dudley J; Cohen JD; Wang P; Fischer CG; Braxton AM; Noë M; Jongepier M; Fernández-Del Castillo C; Mino-Kenudson M; Schmidt CM; Yip-Schneider MT; Lawlor RT; Salvia R; Roberts NJ; Thompson ED; Karchin R; Lennon AM; Jiao Y; Wood LD
Gut; 2021 May; 70(5):928-939. PubMed ID: 33028669
[TBL] [Abstract][Full Text] [Related]
9. Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.
Agostini A; Piro G; Inzani F; Quero G; Esposito A; Caggiano A; Priori L; Larghi A; Alfieri S; Casolino R; Scaglione G; Tondolo V; Cammarota G; Ianiro G; Corbo V; Biankin AV; Tortora G; Carbone C
Nat Commun; 2024 Mar; 15(1):2764. PubMed ID: 38553466
[TBL] [Abstract][Full Text] [Related]
10. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
11. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
12. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
14. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
15. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".
Matsuda R; Miyasaka Y; Yamada Y; Kawata J; Sakihama K; Yamamoto T; Saeki K; Yamamoto H; Ohishi Y; Koga Y; Nakamura M; Oda Y
Virchows Arch; 2020 Dec; 477(6):799-806. PubMed ID: 32468246
[TBL] [Abstract][Full Text] [Related]
16. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights.
Mas L; Lupinacci RM; Cros J; Bachet JB; Coulet F; Svrcek M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201897
[TBL] [Abstract][Full Text] [Related]
17. BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia.
Hallas C; Phillipp J; Domanowsky L; Kah B; Tiemann K
BMC Cancer; 2016 Aug; 16():648. PubMed ID: 27539223
[TBL] [Abstract][Full Text] [Related]
18. Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.
Reid MD; Stallworth CR; Lewis MM; Akkas G; Memis B; Basturk O; Adsay V
Cancer Cytopathol; 2016 Feb; 124(2):122-34. PubMed ID: 26415076
[TBL] [Abstract][Full Text] [Related]
19. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
20. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
